In addition to repurposing clinically available MAOIs, a novel MAOA inhibitor – NMI – was synthesized by conjugating a tumor-targeting near-infrared dye to clorgyline, demonstrating enhanced effectiveness in suppressing prostate tumor growth compared to clorgyline and also providing a good imaging tool for prognostic purposes (49). The gene discussed is MAOA; the disease is prostate neoplasm.